Navigation Links
Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate
Date:9/16/2008

Development of influenza VLP vaccines gains momentum with launch of a Phase

IIa study of Seasonal Influenza Vaccine

ROCKVILLE, Md., Sept. 16 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) announced today vaccination of healthy volunteers in a Phase II clinical trial of its virus-like particle (VLP) based seasonal influenza vaccine. The Phase IIa randomized, placebo controlled clinical trial will evaluate the safety and immunogenicity of different doses of its seasonal influenza VLP vaccine. Specifically, the vaccine will be studied in approximately 300 healthy adults between the ages of 18 to 49 years, who will receive a single injection of either a placebo or an influenza vaccine at doses of 5 mcg, 15 mcg or 30 mcg. The goals of the study are to select a dose for evaluation in a subsequent Phase III efficacy study and to continue the evaluation of safety of its novel influenza VLP vaccines.

VLPs are recombinant structures that mimic the size and shape of a virus but lack genetic material and are therefore incapable of replication. Because they resemble actual infectious particles presenting proteins in the same conformation as on the wild-type virus, they are able to induce potent immune responses. Novavax's VLP vaccine may be differentiated from other influenza vaccines in several ways. First, it includes three viral proteins (incorporated in the vaccine as three separate VLPs) important for inducing a broad immune response including two surface proteins, hemmaglutinin ("HA") and neuraminidase ("NA"), and a core matrix protein, M1. In contrast, most seasonal vaccines consist almost entirely of HA with little or no NA and M1. The HA protein induces antibody that neutralizes or blocks the growth of th
'/>"/>

SOURCE Novavax, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Novavax CEO to Present at BIO CEO & Investor Conference
2. Novavax Enters Into Estrasorb(R) Asset Sale and Supply Agreements with Graceway Pharmaceuticals, LLC
3. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
4. Novavax CEO to Present at the World Vaccine Congress 2008
5. Novavax Opens Its First U.S. Vaccine Plant
6. Novavax Announces Release Date of 2008 First Quarter Financial Results and Investor Conference Call
7. Novavax Reports First Quarter 2008 Financial Results
8. Novavax CEO to Present at ACUMENBioFins 5th Annual Global Healthcare Conference
9. Novavax CEO to Present at FBR Capital Markets 12th Annual Spring Investor Conference
10. Novavax CEO to Present at Piper Jaffray Europe Conference, London, UK
11. Novavax to Join Russell 3000 Index
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... ... July 27, 2015 , ... Production of high tenacity filament yarn of ... in the EU. For instance, it surpassed the EUR 106 million mark (in value ... 2010. Germany is a major producer, while Italy is a key consumer. , ...
(Date:7/27/2015)... -- Research presented at the 2015 AACC Annual Meeting ... that led to a fingerprick Ebola test becoming the ... receive approval from the World Health Organization (WHO). This ... West Africa by identifying suspected ... isolate and treat these patients much faster than is ...
(Date:7/27/2015)... YORK , July 27, 2015 ... today announced the winners of its annual Klerman ... research by scientists who have been supported by ... career scientists to pursue innovative ideas in neurobiological ... "proof" of concept for the early detection, treatment, ...
(Date:7/27/2015)... ... 27, 2015 , ... Visual Assay was named as a finalist for the ... technologies and services of the past year. More than 70 judges selected the finalists, ... will be announced at the 2015 R&D 100 Awards Dinner on November 13 at ...
Breaking Biology Technology:High Tenacity Filament Yarn of Viscose Rayon Consumption to Grow Swiftly in the EU, Forecasts BAC Reports in New Study Available at MarketPublishers.com 2Rapid Ebola Test Could Play Key Role in Efforts to End Lingering Outbreak 2Rapid Ebola Test Could Play Key Role in Efforts to End Lingering Outbreak 3Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 2Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 3Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 4Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 5Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 6Visual Assay® Named Finalist in 53rd Annual R&D 100 Awards 2
... ITMN ) today announced that Daniel G. Welch, Chairman, ... Deutsche,Bank,s 2008 Biotech Boston Confab on November 11, 2008 ... audio webcast of the presentation, investors and other,interested parties ... InterMune,s,corporate website at http://www.intermune.com . The company recommends,logging ...
... Human Genome Sciences,Inc. (Nasdaq: HGSI ) announced ... Confab will be webcast and may be accessed at, ... A member of Human Genome Sciences, senior management team ... at 2:50 PM Eastern Time., Investors interested in ...
... that its executives will be speaking at the following,investor conferences, and ... Credit Suisse Global Health Care Conference, Phoenix, AZ ... Time, Piper Jaffray Health Care Conference, ... 2008 at 2.00 p.m. Eastern Time Accessing Webcasts, To ...
Cached Biology Technology:Cepheid to Webcast Upcoming Financial Presentations 2
(Date:7/2/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/jvft55/next_generation ) ... Biometrics Market by Application, Technology, Function & Geography - ... The next generation biometrics market is expected ... of 17.9% between 2015 and 2020 Travel ... Safran SA ( France ), ...
(Date:6/29/2015)... , June 24, 2015 ... of the "Latin America Biomedical Sensors Market - ... offering. The Latin America Biomedical Sensors market ... CAGR of 2.04% over the period 2014-2020 ... adaptable to the genetic formulation of each individual. These ...
(Date:6/25/2015)... June 25, 2015  TAKE Solutions Ltd., a global ... the United States Patent and Trademark Office (USPTO) for ... leverages TAKE Solutions, Clinical Accelerators to reduce the time ... compared to standardization without the accelerators), thus reducing time ... At the heart of the patented Clinical ...
Breaking Biology News(10 mins):Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3Latin America Biomedical Sensors Market Report 2015-2020 2TAKE Solutions Awarded Patent By USPTO 2
... have found a way to pull pure oxygen from ... and a room-temperature glass of water. ,Because oxygen ... using solar electricity to split water into those elements--a ... One of the chief obstacles to that green-energy scenario ...
... United States, Lyme disease is the most frequently reported ... These animal-borne diseases can make people very sick, and ... crucial to protecting the public. Scientists at the Cary ... $750,000 in grant funding from the U.S. Environmental Protection ...
... University of New Hampshire researchers have tagged one ... They are the first free-swimming leatherbacks ever tagged in ... an endangered species, were tagged July 17, 26 and ... tracking data, allowing scientists to better understand these elusive, ...
Cached Biology News:Water refineries? 2Water refineries? 3EPA funds ground-breaking Lyme disease research 2UNH researchers tag first-ever free-swimming leatherback turtles in New England 2UNH researchers tag first-ever free-swimming leatherback turtles in New England 3
Enables rapid purification of double-stranded DNA fragments = 200 bp, including, for example, PCR reaction products, DNA fragments obtained in restriction enzyme digests, or double-stranded cDNA...
Silica bead method is an economic method of DNA extraction from agarose...
5 minutes from gel band to purified DNA...
BD IMag Anti-Mouse CD90.2 (Thy1.2) Particles-MSC 2 x 109 cells...
Biology Products: